Mastering PSUR Submissions in India: Decoding the CDSCO Deferred Basis Advisory
The landscape of pharmacovigilance (PV) in India demands strict compliance, operational efficiency, and absolute precision. Under the Fifth Schedule of the New Drugs and Clinical Trials (NDCT) Rules, 2019, manufacturers and importers must submit Periodic Safety Update Reports (PSURs) to maintain post-marketing surveillance integrity.
However, a major operational mismatch has historically troubled the industry: the gap between receiving regulatory drug approval and the actual commercial market launch.
Addressing this critical gap, the Central Drugs Standard Control Organization (CDSCO) issued an official advisory (File No. PSUR/4/2026-eoffice) clarifying that PSUR submissions must be managed on a deferred basis relative to the drug's actual launch date.
This guide explains the key directives of the CDSCO advisory and demonstrates how Glaers, a part of Aizilus Technologies, provides both expert consulting services and specialized pharmacovigilance software to help organizations remain fully compliant.
Key Takeaway
CDSCO now requires Marketing Authorization Holders (MAHs) to calculate PSUR timelines from the actual commercial launch date rather than the regulatory approval date, ensuring meaningful post-marketing safety reporting based on real patient exposure.
1. The Core Compliance Directive: Actual Launch vs. Approval Date
The Regulatory Challenge
Traditionally, many Marketing Authorization Holders (MAHs) calculated PSUR submission schedules from the initial regulatory approval date rather than the actual commercial launch date.
When commercialization is delayed, calendar-based reporting creates blank reporting periods with little or no patient exposure, reducing the overall value of post-marketing safety data.
The CDSCO Mandate
The CDSCO advisory introduces two important compliance requirements for all Marketing Authorization Holders.
- Deferred Commencement: PSUR reporting timelines must begin from the actual marketing date of the product, regardless of the regulatory approval date.
- Unified Reporting: Multiple dosage forms, formulations, and approved indications should be combined into a single comprehensive PSUR while maintaining clear segmentation for each population, dosage form, or indication.
Why This Matters
Using the commercial launch date instead of the approval date ensures that PSURs accurately represent real-world patient exposure and meaningful pharmacovigilance data rather than empty reporting periods.
How Glaers Delivers the Solution
Managing deferred submission schedules across multiple pharmaceutical products requires seamless coordination between regulatory, commercial, and safety teams.
- Strategic Consulting Solution: Glaers audits commercialization pipelines, establishes actual market-launch reference dates, redesigns submission calendars, and aligns regulatory planning with commercial operations.
- Advanced Software Solution: The Aizilus pharmacovigilance platform features an intelligent regulatory calendar engine that automatically calculates six-month and annual PSUR schedules using the actual commercial launch date.
2. Simplifying the Single-Report Rule for Diverse Product Forms
The Regulatory Challenge
Preparing separate PSURs for multiple strengths, dosage forms, and indications often results in repetitive documentation and increased administrative workload.
The CDSCO advisory recommends maintaining a single consolidated PSUR while clearly separating safety information for each formulation, indication, and patient population within the report.
Single Corporate PSUR Submission
- Formulation A (Tablets): Segmented patient exposure data.
- Formulation B (Injection): Independent safety profile.
- Multiple Indications: Separate benefit-risk evaluations for each approved indication.
How Glaers Delivers the Solution
Managing safety information across numerous formulations requires both intelligent software and experienced pharmacovigilance professionals.
- Advanced Software Solution: The Aizilus pharmacovigilance platform consolidates global and local Individual Case Safety Reports (ICSRs) into one centralized database.
- The system automatically classifies safety information using MedDRA coding, separates data by formulation, indication, and patient demographics, and prepares structured PSUR outputs compatible with SUGAM portal submission requirements.
- Strategic Consulting Solution: Glaers' medical writing specialists review the aggregated safety data, prepare scientific evaluations, develop benefit-risk assessments, and structure clear sub-population analyses for regulatory submission.
3. Maintaining Audit Readiness on the SUGAM Portal
The Regulatory Challenge
Organizations that fail to synchronize their pharmacovigilance systems with deferred PSUR timelines may encounter compliance observations during regulatory inspections.
Missing reporting deadlines, maintaining duplicate tracking systems, or submitting inconsistent data can delay product renewals and trigger regulatory notices from the Post Marketing Drugs Safety Monitoring Division.
How Glaers Delivers the Solution
Achieving complete audit readiness requires validated software, standardized operating procedures, and continuous compliance monitoring.
- Strategic Consulting Solution: Glaers updates Standard Operating Procedures (SOPs), integrates deferred PSUR tracking into Quality Management Systems (QMS), and performs mock inspections to verify regulatory readiness.
- Advanced Software Solution: The Aizilus cloud-based platform complies with GAMP 5 validation principles and maintains secure electronic audit trails for every modification, review, approval, and SUGAM submission.
- Electronic signatures, validation records, and automated compliance logs provide Pharmacovigilance Officers-in-Charge (PVOICs) with complete confidence during regulatory inspections.
Compliance Benefit
Combining validated pharmacovigilance software with expert regulatory consulting helps organizations simplify PSUR management, eliminate duplicate reporting, improve inspection readiness, and maintain continuous compliance with CDSCO expectations.
Summary Checklist for Compliance Alignment
To ensure your pharmacovigilance processes are fully aligned with the latest CDSCO advisory, review the following compliance checklist.
Audit Launch Dates
Cross-check the actual commercial launch dates of all approved products against your existing PSUR tracking schedules to eliminate reporting discrepancies.
Consolidate Duplicate Trackers
Merge separate tracking records for different strengths, formulations, and indications into a single master reporting framework.
Update Internal SOPs
Revise your Standard Operating Procedures to replace approval-date based tracking with actual commercial launch-date driven reporting.
Deploy Validated Systems
Replace manual spreadsheets with validated pharmacovigilance software capable of automating PSUR scheduling, data segregation, and regulatory reporting.
Why This Matters
The CDSCO Deferred Basis Advisory represents an important evolution in India's pharmacovigilance framework. Organizations that align their internal processes with actual commercial launch dates can significantly improve reporting quality, eliminate unnecessary duplication, and remain inspection-ready throughout the product lifecycle.
Accelerate Your PSUR Compliance with Glaers
Managing deferred PSUR timelines, consolidated reporting, and SUGAM submissions requires both regulatory expertise and a modern pharmacovigilance platform.
Glaers, together with Aizilus Technologies, combines experienced pharmacovigilance consultants with a GAMP 5 validated cloud-based safety database to help pharmaceutical organizations automate compliance, simplify reporting, strengthen audit readiness, and maintain complete regulatory confidence.
Whether your organization needs assistance with PSUR planning, regulatory consulting, software implementation, medical writing, or long-term pharmacovigilance operations, Glaers delivers an integrated solution designed specifically for the life sciences industry.
Partner with Glaers
Accelerate your regulatory compliance and safeguard patient safety with expert pharmacovigilance consulting and enterprise-grade pharmacovigilance software from Glaers.